1 / 9

Empowering Stakeholders in Drug Policy Making: Research Evidence for Ethical Drug Advertisement

This research aims to collect data on drug advertisement practices, inform stakeholders in policy making about unethical drug promotion, evaluate changes, and propose interventions. The study focuses on the impact of regulations on drug advertisements to ensure rational drug use in the context of increasing drug availability and competition. The results show improvements in regulatory statuses and promotional practices but highlight ongoing challenges in enforcing ethical standards in drug advertising.

adriann
Download Presentation

Empowering Stakeholders in Drug Policy Making: Research Evidence for Ethical Drug Advertisement

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EMPOWERING STAKEHOLDERS IN DRUG POLICY MAKING BY RESEARCH EVIDENCE TO IMPROVE REGULATIONS FOR ETHICAL DRUG ADVERTISEMENT TOWARD RATIONAL DRUG USE Pham Huy Dung and Nguyen Thi Kim Chuc Institute for Health Environment and Development

  2. Problem Statement: Consequences of the socio-economic reform and the health sector reform in Vietnam: • Drugs become more available -> no more shortage of drugs • Too many drugs -> foreign and local companies compete for drug sell -> increasing public spending on drugs and making drug advertisement unethical, which could have negative impact on rational drug use.

  3. Objectives • Collect information on drug advertisement • Inform stakeholders in drug policy making about research evidence on unethical drug advertisement for them to improve regulations for drug promotion toward rational drug use • Evaluate change in drug advertisement • Propose new intervention (regulation)

  4. Design,Setting and Population Design: Pre post evaluation of the regulatory status and its impact on advertisements to the public, on advertisements to doctors as well as on promotional practice. Setting and Population: Various stakeholders in drug policy making: the Committee for social affairs of the National Assemble, the Prime Minister Research Commission, the Committee of Science and Education of the Leading Party (the Communist Party), various departments of the Ministry of Health, various non-government association (the Youth Federation, the Women Union, etc.)

  5. Intervention • Research results from a study on country status, regulatory status, drug advertisements to the public, advertisements to doctors and promotional practice in 1998 were used to inform stakeholders in drug policy making about evidence of unethical aspects in drug promotion harmful to rational drug use • The information process has been implemented through meetings, seminars and workshops using the Meta analysis method

  6. Results: Improvement of the Regulatory Status • Ordinance of the national Assemble 39/2001/PL for advertisement • Ordinance of the President November 30,2001 for advertisement • Decree of the Government 59/2002 for advertisement • Decree of the Ministry of Health 2557/2002/QD-BYT for drug advertisements • Decree of the Ministry of Health on the list of drugs that are allowed for advertisement on March 12, 2003

  7. Results: Advertisements and Promotional Practice • Advertisements • Advertisement to the general public: no improvement in generic names and contra-indications, some improvement in FDA approval (0%->22% in radios and TVs; 0%->47% in magazines) • Advertisement to doctors: no improvement in generic names, some improvement in contra-indications (5.6%->55.6%) and in FDA approval (0%-> 34.6%) • Promotional Practice • Improvement in knowledge among doctors, medical representatives and manufacturers

  8. Discussion and Conclusions • Drug advertisement should respond to requirement of drug information • Rapid effect for improvement of the regulatory status • Low effect of the regulatory status on practice • Enforcement of regulations could control some issues such as generic name, contra-indications, FDA approval, etc. • How to control medical representatives?

More Related